text: Ibrutinib (<< Imbruvica(R) >>) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits [[ B-cell antigen receptor ]] signalling downstream of BTK.